Please login to the form below

Not currently logged in
Email:
Password:

Acambis patent boost

Transcripts reveal that ITC could come down on side of UK firm in dispute over smallpox vaccine

Shares in Acambis received a boost after lawyers from the US International Trade Commission (ITC) appeared to back the UK vaccine maker in its dispute with Danish rival, Bavarian Nordic, over patents for a smallpox vaccine.

The ITC released transcripts of the public sessions of a hearing on the case concerning the vaccine, called MVA.

Analyst Jonathan Senior at Evolution Securities told Reuters that although the ITC was yet to make a judgment, in its opening statement it had come down on the side of Acambis, saying the firm ìdidn't have a case to answerî.

ìThey're saying Bavarian Nordic's patents are not valid,î he said.

Acambis and Bavarian Nordic are fiercely competing for a lucrative US government contract to supply the vaccine.

In May, Acambis and US marketing partner Baxter, which manufactures the MVA vaccine, MVA3000, in Austria, filed opposition to a European patent granted to Bavarian Nordic regarding a weakened form of the vaccine, targeted at those who are immunocompromised, including those with HIV. Bavarian Nordic had claimed the two companies would be infringing its patents if they sell their smallpox vaccine to the US government.

ITC lawyers, acting as a third party, have told the ITC judge that Bavarian Nordic's patents are invalid and also unenforceable.

The ITC judge's initial determination on the case is expected around the end of August.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Grace Communications

Grace Communications is an award winning, independent, full service, creative communications agency specialising in solving problems for healthcare brands....

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics